JPRN-jRCTs031180013进行中（未招募）2 期
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarker - IMMUNITY-ONE(NEJ029B)
Kagamu Hiroshi0 个研究点目标入组 60 人开始时间: 2018年8月7日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Advanced non-small-cell lung cancer
- •2.History of one regimen or more cytotoxic chemotherapy
- •3.Twenty years and over
- •4.Expect survival for more than 3 months
- •5.ECOG PS 0-1
- •6.Having measurable leasions
- •7.Main organs function is maintained
- •8.With consent of the person or the substitute
排除标准
- •1.Having history of immuno-checkpoint-inhibitor
- •2.Having history of autoimune disease
- •3.Having active or symptomatic interstitial lung disease
- •4.With infections requiring systemic treatment
- •5.Having symptomatic brain metastasis
- •6.Having poorly controlled diabetes
- •7.Having active liver disease
- •8.Having history of severe hypersensitivity
- •9.Patient judged inappropriate by the attending physician
研究者
相似试验
已完成
不适用
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkernon-small-cell lung cancerJPRN-UMIN000028468orst East Japan Study Group(NEJSG)60
已完成
2 期
A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study10027412pleural mesotheliomaNL-OMON41970Antoni van Leeuwenhoek Ziekenhuis33
进行中（未招募）
不适用
ivolumab in patients with progressive malignant pleural mesothelioma: NivoMesA single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes StudyMedDRA version: 17.1Level: LLTClassification code 10027408Term: Mesothelioma malignant advancedSystem Organ Class: 100000004864EUCTR2014-003935-20-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
进行中（未招募）
1 期
Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the SkiCTIS2024-513637-20-00Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH61
招募中
2 期
Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin2024-513637-20-00Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH61